COVID-19: NIAID Clinical Research Support Services (CRSS)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 272201700078C-P00013-9999-2

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $385,065,810
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    BAMBRA STROKES
  • Research Location

    United States of America
  • Lead Research Institution

    PPD DEVELOPMENT LP
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The purpose of this contract is to provide a broad range of research support services to the current and evolving NIAID-supported clinical research portfolio. The contract enables the NIAID to establish and maintain the robust and flexible resources required to facilitate and advance infectious disease research and establish and maintain support for product development activities for high priority vaccine, other prevention and therapeutic approaches. Support will be provided in four broad clinical research areas: a) clinical research management; b) clinical site assistance; c) clinical trial management and d) clinical trial compliance. This project will provide support services for the COVID-19 ACTIV2 Outpatient Monoclonal Antibodies And Other Therapies clinical trial.